Table 3.
Type of first- and second-line regimens currently used by the participating sites
| Country, city, clinic | First-line regimen | Second-line regimen |
|---|---|---|
| Cambodia | ||
| Phnom Penh, National Centre for HIV/AIDS, Dermatology and STD, National Pediatric Hospital | AZT/d4T + 3TC + NVP/EFV | ABC + ddI + LPV/r |
| Indonesia | ||
| Jakarta, Cipto Mangunkusumo Hospital | AZT/d4T + 3TC + NVP/EFV | TDF + ddI + LPV/r |
| India | ||
| Chennai, YRG care | AZT + 3TC + NVP/EFV | TDF/ABC + 3TC/FTC + LPV/r |
| Malaysia | ||
| Kota Bharu, Hospital Raja Perempuan Zainab II | AZT + 3TC + NVP/EFV | d4T/ddI + LPV/r |
| Kota Kinabalu, Hospital Likas | ||
| Kuala Lumpur, Hospital Kuala Lumpur | AZT/d4T + 3TC + NVP or AZT/ddi + NVP/EFV | 2NRTI + LPV/r |
| Penang, Penang Hospital | AZT/d4T + 3TC + NVP | 2NRTI + LPV/r |
| Thailand | ||
| Bangkok, HIVNAT | AZT/d4T + 3TC + NVP/EFV PI-based for infants exposed to NVP | NRTI + boosted PI/double boosted PI depends on drug resistance |
| Bangkok, Siriraj Hospital | AZT/d4T + 3TC + NVP/EFV | PI-based regimen (LPV/r) |
| Chiang Mai, Chiang Mai University | AZT/d4T + 3TC + NVP/EFV | 2NRTI + LPV/r or double boosted PI |
| Chiang Rai, Chiang Rai Regional Hospital | AZT/d4T + 3TC + NVP/EFV | 2NRTI + LPV/r |
| Khon Kaen, Khon Kaen University | AZT + 3TC + EFV if < 3 years: AZT + 3TC + NVP | 3TC + EFV + LVR/r |
| Vietnam | ||
| Hanoi, National Hospital of Pediatrics | AZT/d4T + 3TC + NVP/EFV | ABC + ddI + LPV/r/NFV |
| Ho Chi Minth City, Children’s Hospital No.1 | AZT/d4T + 3TC + NVP/EFV | ABC + ddI + LPV/r/NFV |
AZT: aidovudine; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; EFV: efavirenz; DDI: didanosine; ABC: abacavir; TDF: tenofovir; LPV/r: lopinavir\ritonavir low dose; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor.